According to recent research carried out at the University of Alberta, intranasal administration of anti-inflammatory drug helps reduce disease progression reveals preclinical models of multiple sclerosis.
“In preclinical trials, administering anti-inflammatory drugs to mice helps prevent damage to brain cells, and effectively slows the progression of the disease, showed one of the team members of the study.
In fact, multiple sclerosis is a devastating illness which doesn’t have a cause, and no cure. The researchers involved vied to understand the disease to develop effective treatments.
Meanwhile, nerves in the brain are like insulated wires. However, in multiple sclerosis, initially, there is a loss of insulation, and eventually loss of wire. These losses are caused by inflammation.
Inflammation in Multiple Sclerosis key Research Area
The inflammation in multiple sclerosis is the main research interest,” sated one of the researchers involved.
In fact, the key interest of the research group is inflammasomes –molecules that account for the activation of inflammatory response in the body. Therefore, for diseases such as multiple sclerosis, the response must be controlled to stop the progression. A drug called VX-765 that has been identified is a strong candidate therapy for multiple sclerosis patients.
For multiple sclerosis, the drug acts by inhibiting caspase – 1, a constituent of inflammasomes that promotes damaging inflammation in the body. In earlier research, the team of researchers saw beneficial results by administering insulin intranasally for some other models of brain inflammation, thus, the team decided to go with this delivery route again. For mouse models, the lead researcher dissolved VX-765 in a fluid and then administered the mixture into the nose.
Meanwhile, for patients, the need of the drug is less.